Meningeome
Begutachtet von Dr John Cox, MRCGPZuletzt aktualisiert von Dr Colin Tidy, MRCGPZuletzt aktualisiert 24. Juli 2015
Erfüllt die Anforderungen des Patienten Richtlinien des Patienten
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Diese Seite wurde archiviert.
Es wurde kürzlich nicht überprüft und ist nicht auf dem neuesten Stand. Externe Links und Referenzen funktionieren möglicherweise nicht mehr.
Medizinische Fachkräfte
Fachartikel sind für die Nutzung durch Gesundheitsfachkräfte konzipiert. Sie werden von britischen Ärzten verfasst und basieren auf Forschungsergebnissen sowie britischen und europäischen Richtlinien. Sie finden möglicherweise die Gehirntumore Artikel nützlicher oder einer unserer anderen Gesundheitsartikel.
In diesem Artikel:
See related separate articles Brain Tumours in Adults und Brain Tumours in Children.
Meningiomas are mostly benign tumours which arise from the dura mater and are usually slow-growing. Meningiomas usually form well-circumscribed lesions but, rarely, can be more diffuse - eg, when they grow next to the sphenoid ridge and are called 'meningioma en plaque'. Meningiomas occur either intracranially or within the spinal canal. Meningiomas can be graded in various ways - eg, site of origin, encroachment of surrounding tissues and histological grading. The most common system used is the World Health Organization (WHO) classification:1
Grade I (generally benign): meningothelial, psammomatous, secretory, fibroblastic, angiomatous, lymphoplasmacyte-rich, transitional, microcystic, metaplastic.
Grade II (there is a higher rate of recurrence after surgery, especially if a resection is incomplete): clear-cell, chordoid, atypical. Chordoid type has been associated with Castleman's disease (an uncommon lymphoproliferative disorder).
Grade III (anaplastic): papillary (rare and mostly seen in children), rhabdoid and anaplastic. Grade III meningiomas are malignant with a high rate of local invasion, recurrence and metastases.
Lesen Sie unten weiter
Epidemiologie2
They are the most common tumours in the central nervous system, accounting for about one-third of all adult central nervous system tumours.34
The reported annual incidence of cerebral meningiomas ranges from 1.3/100,000 to 7.8/100,000.5
There is a female:male ratio of 2:1.
2-3% of the population have asymptomatic meningiomas and 8% have multiple meningiomas.
Aetiology and risk factors
Zurück zum InhaltAetiology is not known and most cases are sporadic.1
Some are increased in the presence of certain genetic disorders - eg, loss of chromosome 22 and presence of neurofibromatosis type 2.16
Other risk factors include advanced age, cranial irradiation, Kopfverletzung und Brustkrebs (although causality not determined).23
Lesen Sie unten weiter
Site (the most common first)
Zurück zum InhaltSkull vault.
Skull base - eg, sphenoid wing and petrous ridge.
Sites of dural reflection - eg, falx cerebri and tentorium cerebelli.
Optic nerve sheath.
Choroid plexus.
Spine (rarely).
Outside the craniospinal axis (very rarely) - eg, the ear, temporal bone and foot.
Proliferation markers
Zurück zum InhaltProliferationsmarker liefern Informationen über die Wahrscheinlichkeit eines Rückfalls. Zum Beispiel sind MIB-1 und Ki67 in höheren Konzentrationen in Tumoren vorhanden, die wahrscheinlich wiederkehren.27 However, further work is needed to clarify the role of proliferation markers and prognosis.
Meningiomas can also express progesterone receptors.8
Higher levels of progesterone receptors have been reported to be associated with a lower frequency of recurrence and a better prognosis.
More than 70% of meningiomas express somatostatin receptors which can be used with radiological imaging, especially when looking for local recurrence.29
Lesen Sie unten weiter
Präsentation
Zurück zum InhaltMeningiomas present as a space-occupying lesion.
Seizures - focal or generalised are common with meningiomas.
Raised intracranial pressure effects - eg, obstructive hydrocephalus with headache.
Neuropsychological effects - eg, change in personality and disinhibition in frontal lesions.
Neurological features - eg, cranial nerve palsies depending on location of a meningioma or language dysfunction.
Transient ischaemic attack and intracranial haemorrhage may also be seen.
Meningiomas that compress the visual pathways cause visual field defects.
Other rare presentations include:
Meningiomas near the sella turcica may produce panhypopituitarism.
Spinal meningiomas may cause Brown-Séquard's syndrome.
Differentialdiagnose
Zurück zum InhaltThis is as for raumfordernde Läsionen. Meningiomas can be discovered incidentally when patients are investigated for other conditions. Other lesions which may also affect the dura mater include:
Other primary brain tumours.
Metastases from lymphoma and adenocarcinoma.
Inflammatory disorders - eg, Sarkoidose.
Infections - eg, Tuberkulose.
Untersuchungen
Zurück zum InhaltImaging - MRI is superior to CT scanning as it shows the dural origin. Meningiomas are well-defined, extra-axial lesions. They may show central cystic degeneration and oedema of nearby white matter.
Endovascular angiography allows pre-operative assessment of the blood supply of the tumour and its proximity to vital vascular structures.
Biopsy - stereotactic biopsy via a skull burr-hole or open exploration (craniotomy).
Behandlung
Zurück zum InhaltManagement will depend on the clinical presentation, age of the patient, site of the tumour and size of the tumour. For example, an elderly patient with multiple comorbidities who is discovered incidentally to have a small, asymptomatic meningioma, can be managed conservatively. This usually consists of yearly MRI scans for three years and then just clinical follow-up if nothing new has developed.2
Endovascular embolisation
This involves embolisation of the blood supply to the meningioma - eg, coil or glue applied endovascularly to the meningeal artery.10
This is usually performed before surgical removal, as it reduces the amount of blood loss.11
It has also been performed as the primary therapy in those unsuitable for surgery.
Embolisation usually causes necrosis of the meningioma, which can cause some histological doubt when specimens are examined postoperatively.2
Chirurgische Entfernung
The tumour and its dural base are removed. Total excision is the aim but this is not always technically possible.
Surgery may be complicated by invasion into local structures - eg, parasagittal tumours invading into the cerebral dural sinus.
Stereotactic radiosurgery can provide excellent local tumour control.
Strahlentherapie
Radiotherapy is used in the following:
Incomplete resection.
Following recurrence of meningioma.
High-grade meningiomas with atypia or anaplasia on histology.
In diesen klinischen Szenarien ist die Anwendung der Strahlentherapie mit einem besseren Ergebnis verbunden. Zum Beispiel wurde in einer Studie die stereotaktische Radiochirurgie mit einer besseren Tumorkontrolle (etwa 10 %) und weniger Komplikationen in Verbindung gebracht.12 However, a recent paper has shed some doubt on how useful radiotherapy is in meningiomas.13
Stereotactic application of radiotherapy has further benefits compared with traditional radiotherapy. This includes less damage to undiseased tissue and better five-year control rates.21415
Radiotherapy is successful and may be used as the primary therapy for tumours, especially inaccessible meningiomas - eg, optic nerve lesions.2
Chemotherapy and molecular agents
Chemotherapy has so far shown disappointing results and has been reserved for when surgery and radiotherapy have failed to control the disease.
Chemotherapeutic regimens involving hydroxyurea have been used but with little success.1617
Other drugs studied include temozolomide, RU-486 and interferon alfa, which have also shown disappointing results.
Prognose
Zurück zum InhaltAtypical and anaplastic types of meningiomas can rarely metastasise.
Completely resected meningiomas usually have an excellent prognosis. The five-year survival for typical meningiomas is more than 80%; however, this falls to below 60% in malignant and atypical meningiomas.17
Exklusive Updates für medizinisches Fachpersonal
Bleiben Sie informiert mit den neuesten klinischen Updates, professionellen Einblicken und evidenzbasierten Leitlinien. Der Patient Pro-Newsletter stellt wesentliche Inhalte für Gesundheitsfachkräfte zusammen – direkt in Ihren Posteingang geliefert.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.
Weiterführende Literatur und Referenzen
- Riemenschneider MJ, Perry A, Reifenberger G; Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006 Dec;5(12):1045-54.
- Whittle IR, Smith C, Navoo P, et al; Meningiomas. Lancet. 2004 May 8;363(9420):1535-43.
- Saraf S, McCarthy BJ, Villano JL; Update on meningiomas. Oncologist. 2011;16(11):1604-13. doi: 10.1634/theoncologist.2011-0193. Epub 2011 Oct 25.
- Murnyak B, Bognar L, Klekner A, et al; Epigenetics of Meningiomas. Biomed Res Int. 2015;2015:532451. doi: 10.1155/2015/532451. Epub 2015 May 25.
- Baldi I, Engelhardt J, Bonnet C, et al; Epidemiology of meningiomas. Neurochirurgie. 2014 Sep 20. pii: S0028-3770(14)00112-X. doi: 10.1016/j.neuchi.2014.05.006.
- Simon M, Bostrom JP, Hartmann C; Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery. 2007 May;60(5):787-98; discussion 787-98.
- Carvalho LH, Smirnov I, Baia GS, et al; Molecular signatures define two main classes of meningiomas. Mol Cancer. 2007 Oct 15;6:64.
- Omulecka A, Papierz W, Nawrocka-Kunecka A, et al; Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol. 2006;44(2):111-5.
- Durand A, Champier J, Jouvet A, et al; Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008 Sep-Oct;27(5):334-45.
- Qureshi AI; Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet. 2004 Mar 6;363(9411):804-13.
- Rodiek SO, Stolzle A, Lumenta ChB; Preoperative embolization of intracranial meningiomas with Embosphere microspheres. Minim Invasive Neurosurg. 2004 Oct;47(5):299-305.
- Buckner JC, Brown PD, O'Neill BP, et al; Central nervous system tumors. Mayo Clin Proc. 2007 Oct;82(10):1271-86.
- Marcus HJ, Price SJ, Wilby M, et al; Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg. 2008 Aug;22(4):520-8.
- Elia AE, Shih HA, Loeffler JS; Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus. 2007;23(4):E5.
- Kondziolka D, Lunsford LD, Flickinger JC; The application of stereotactic radiosurgery to disorders of the brain. Neurosurgery. 2008 Feb;62 Suppl 2:707-19; discussion 719-20.
- Modha A, Gutin PH; Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50.
- Marosi C, Hassler M, Roessler K, et al; Meningioma. Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71. Epub 2008 Mar 14.
- Wen PY, Drappatz J; Novel therapies for meningiomas. Expert Rev Neurother. 2006 Oct;6(10):1447-64.
- Norden AD, Drappatz J, Wen PY; Targeted drug therapy for meningiomas. Neurosurg Focus. 2007;23(4):E12.
Lesen Sie unten weiter
Über den AutorVollständige Biografie anzeigen

Dr Colin Tidy, MRCGP
Allgemeinmediziner, Medizinischer Autor
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr. Colin Tidy ist ein NHS-Arzt mit Sitz in Oxfordshire.
Über den RezensentenVollständige Biografie anzeigen

Dr John Cox, MRCGP
MA, MB, B Chir, DCH, DRCOG, MRCP (UK), MRCGP
Dr John Cox worked as a Medical Registrar in the UK and New Zealand and as a locum Physician in New Zealand.
Artikelverlauf
Die Informationen auf dieser Seite wurden von qualifizierten Klinikern verfasst und begutachtet.
24. Juli 2015 | Neueste Version

Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.

Fühlen Sie sich unwohl?
Bewerten Sie Ihre Symptome online kostenlos